Patents Assigned to Systemix
  • Patent number: 5516977
    Abstract: Immunocompromised hosts comprising xenogeneic fetal lymph node tissue implanted in the ear pinna are provided. The chimeric hosts are prepared by inserting the xenogeneic lymph node tissue into the ear pinna and closing the incision. The tissue is found to be rapidly vascularized and can be productively infected with HIV.
    Type: Grant
    Filed: December 17, 1993
    Date of Patent: May 14, 1996
    Assignee: Systemix, Inc.
    Inventors: Brian Ford, Hideto Kaneshima
  • Patent number: 5476997
    Abstract: A human hematopoietic system is provided in an immunocompromised mammalian host, where the hematopoietic system is functional for extended periods of time. Particularly, human fetal liver tissue and human fetal thymus is introduced into an appropriate site of a young immunocompromised mouse at a site supplied with a vascular system, whereby the fetal tissue results in novel formation of functional human bone marrow tissue.
    Type: Grant
    Filed: May 17, 1994
    Date of Patent: December 19, 1995
    Assignee: Systemix, Inc.
    Inventors: Hideto Kaneshima, Reiko Namikawa, Joseph M. McCune
  • Patent number: 5466572
    Abstract: Hematopoietic cell populations are separated to provide cell sets and subsets as viable cells with high purity and high yields, based on the number of original cells present in the mixture. High-speed flow cytometry is employed using light characteristics of the cells to separate the cells, where high flow speeds are used to reduce the sorting time.
    Type: Grant
    Filed: April 25, 1994
    Date of Patent: November 14, 1995
    Assignee: Systemix, Inc.
    Inventors: Dennis T. Sasaki, Gerrit J. Van den Engh, Anne-Marie Buckie
  • Patent number: 5434341
    Abstract: Methods and chimeric immunocompromised hosts comprising functional xenogeneic organs are provided, particularly hematopoietic organs, where the xenogeneic organ is engrafted into a mammary fat pad. Exemplary is the engrafting of lymph node with mesenteric tissue comprising small portions of blood vessels transplanted into mammary fat pad of a scid/scid mouse. The engraftment in the mammary fat pad provides for efficiencies in transplantation, higher success rate of transplantation, and improved growth of the transplanted organ.
    Type: Grant
    Filed: August 7, 1992
    Date of Patent: July 18, 1995
    Assignee: Systemix, Inc.
    Inventor: Henry C. Outzen
  • Patent number: 5411749
    Abstract: Human lymphoid tissue is introduced into an immunocompromised host to provide opportunities to investigate the effect of stimuli on the human immune system and obtain information and products from the stimulus. Particularly, methodology is provided for the production of human monoclonal antibodies by introducing lymphoid tissue into an immunocompromised host, stimulating the B-lymphocytes with an appropriate immunogen, harvesting the tissue and immortalizing and/or cloning the B-lymphocytes under conditions to obtain a stable supply of monoclonal antibodies.
    Type: Grant
    Filed: December 23, 1992
    Date of Patent: May 2, 1995
    Assignee: Systemix, Inc.
    Inventors: Susan K. Mayo, Reiko Namikawa, Hideto Kaneshima, Joseph M. McCune
  • Patent number: 5409813
    Abstract: The invention provides a method for both the positive and negative selection of at least one mammalian cell population from a mixture of cell populations utilizing a magnetically stabilized fluidized bed. One desirable application of this method is the separation and purification of mammalian hematopoietic cells. Target cell populations include human stem cells.
    Type: Grant
    Filed: September 30, 1993
    Date of Patent: April 25, 1995
    Assignee: SyStemix, Inc.
    Inventor: Richard M. Schwartz
  • Patent number: 5147784
    Abstract: Methodology is provided for identifying the presence of human T-lymphocyte progenitor cells. Human thymus tissue is depleted of endogenous lymphold cells, repopulated with a human cellular composition which is HLA mismatched with the thymus tissue and implanted into a vascularizable site in an immunocompromised host. After at least about 2 weeks, the tissue may be assayed for the presence of the HLA mismatched T-lymphocytes as indicative of human T-lymphocyte progenitors in this cellular composition.
    Type: Grant
    Filed: April 12, 1990
    Date of Patent: September 15, 1992
    Assignee: SyStemix, Inc.
    Inventor: Bruno Peault
  • Patent number: 5061620
    Abstract: Human hematopoietic stem cells are provided by separation of the stem cells from dedicated cells. The stem cells may than be maintained by regeneration in an appropriate growth medium. Means are provided for assaying for the stem cells as to their capability for producing members of each of the hematopoietic lineages.
    Type: Grant
    Filed: March 30, 1990
    Date of Patent: October 29, 1991
    Assignee: SyStemix, Inc.
    Inventors: Ann Tsukamoto, Charles M. Baum, Yukoh Aihara, Irving Weissman